Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 12, 2024 5:52pm
136 Views
Post# 36359971

RE:Insider activity.

RE:Insider activity. There's no "free money" in the granting of options, only the right to purchase of shares of the companyat the price the options were granted and by a certain date. Should the shares nott be acquired by the 'maturity date'- the options expire and the allottted (reserved) shares are returned to the company's treasury.. 

So, in Coffey's case he let 331, 267 options expire without being exercised and was only granted 13,061 options in return - thus having the difference removed from the total number of diluted shares ONCY reports each quarter. In Kirk Look's case, he let 270,700  options expire without being exercised and was only granted 20,700 options in return

In addition, on November 27, 2024 Matt Coffey let 227,163 options expire without being exercised, while being granted 11,260 options in return.
<< Previous
Bullboard Posts
Next >>